These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 35972620)
1. A + T ± status across MCI and dementia due to AD: a clinic-based, retrospective study. Verde F; Aiello EN; Milone I; Giacopuzzi Grigoli E; Dubini A; Ratti A; Poletti B; Ticozzi N; Silani V Neurol Sci; 2022 Nov; 43(11):6547-6550. PubMed ID: 35972620 [TBL] [Abstract][Full Text] [Related]
2. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related]
3. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related]
4. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
5. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478 [TBL] [Abstract][Full Text] [Related]
6. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792 [TBL] [Abstract][Full Text] [Related]
8. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311 [TBL] [Abstract][Full Text] [Related]
11. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia. Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study. Pais M; Loureiro J; do Vale V; Radanovic M; Talib L; Stella F; Forlenza O J Alzheimers Dis; 2021; 81(3):949-962. PubMed ID: 33843685 [TBL] [Abstract][Full Text] [Related]
15. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913 [TBL] [Abstract][Full Text] [Related]